Protara Therapeutics, Inc.
Clinical-stage biopharma developing therapies for cancer and rare diseases.
TARA | US
Overview
Corporate Details
- ISIN(s):
- US74365U1079
- LEI:
- Country:
- United States of America
- Address:
- 345 PARK AVENUE SOUTH, 10010 NEW YORK
- Website:
- https://protaratx.com/
Description
Protara Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on advancing transformative therapies for cancer and rare diseases. The company's lead candidate is TARA-002, an investigational cell therapy based on the immunopotentiator OK-432. TARA-002 is being evaluated for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs), for which it has received Rare Pediatric Disease Designation from the U.S. Food and Drug Administration. Protara's pipeline also includes IV Choline Chloride, an investigational phospholipid substrate replacement therapy for patients on parenteral support who are choline deficient, with the potential to become the first FDA-approved intravenous choline formulation for this patient group.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Protara Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Protara Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Protara Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
